Navigation Links
Drug commonly used to treat bipolar disorder dramatically increases lifespan in worms
Date:10/30/2007

Nematode worms treated with lithium show a 46 percent increase in lifespan, raising the tantalizing question of whether humans taking the mood affecting drug are also taking an anti-aging medication. Results of the Buck Institute study, led by faculty member Gordon J. Lithgow, PhD, are currently published online in the Journal of Biological Chemistry.

Lithium has been used to treat mood affective disorders, including bipolar disease for decades. While the drug has been shown to protect neurons, the underlying mechanism of its therapeutic action is not understood. In humans, lithiums therapeutic range is very limited and the drug has serious side effects. The research provides a novel genetic approach to understanding how lithium works and highlights the utility of using the nematode C. elegans as a research subject in the field of pharmacogenetics. Pharmocogenetics involves the study of genetic factors that influence an organisms reaction to a drug.

In the study, scientists discovered that longevity was increased in the worms when the lithium turned down the activity of a gene that modulates the basic structure of chromosomes.

Lithgow believes that lithium impacts many genes. Understanding the genetic impact of lithium may allow us to engineer a therapy that has the same lifespan extending benefits, said Lithgow. One of the larger questions is whether the lifespan extending benefits of the drug are directly related to the fact that lithium protects neurons. The process of normal aging in humans is intrinsically linked to the onset of neurodegenerative disease. However, the cellular changes and events due to aging that impact neurodegeneration are not yet understood said Lithgow. Studies involving compounds such as lithium could provide breakthroughs in the attempt to understand the biomedical link between aging and disease. Lithgow and his lab are now surveying tens of thousands of compounds for affects on aging.

The study highlights the efficacy of using C. elegans as a new way of studying drug toxicity and genetic impacts of compounds currently in drug development or already in use in humans. The use of simple model organisms with well developed genetic tools can speed the identification of molecular targets, said Lithgow. This could facilitate the development of improved therapies for diseases.


'/>"/>

Contact: Kris Rebillot
krebillot@buckinstitute.org
415-209-2260
Buck Institute for Age Research
Source:Eurekalert

Related biology news :

1. Harmful Bacterium Commonly Found in Poultry May Survive Refrigeration and Frozen Storage Combined
2. Ibruprofen and other commonly used painkillers for treating inflammation may increase the risk of heart attack
3. Commonly used antidepressants may also affect human immune system
4. Protein discovery could unlock the secret to better TB treatment
5. Topical treatment shown to inhibit HIV and herpes simplex virus infection
6. Antarctic ice shelf retreats happened before
7. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
8. Researchers add new tool to tumor-treatment arsenal
9. Discovery Could Lead To Novel Approaches In HIV Treatment
10. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
11. FDA Approves New Drug to Treat Type I and Type II Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2016)... innovation leader in attendance control systems is proud to announce the introduction of fingerprint ... sure the right employees are actually signing in, and to even control the opening ... ... ... Photo ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
Breaking Biology Technology: